Tuberc Respir Dis.  2008 Aug;65(2):79-90.

Treatment of Latent Tuberculosis Infection in Korea

• Shim TS
• Koh WJ
• Yim JJ
• Lew WJ

Abstract

No abstract available.

MeSH Terms

Korea
Latent Tuberculosis

Figure

• 

  Figure 1 Treatment of children younger than 6 years who are contacts of people with sputum smear-positive TB (Korean CDC, 2008).

Reference

1. Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics. 2004. 114:S1175–S1201.

2. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000. 49:1–51.

3. Korean Academy of Tuberculosis and Respiratory Diseases. Guideline for the management of tuberculosis. 2005. Seoul: Korean Academy of Tuberculosis and Respiratory Diseases.

4. National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2006. London: National Institute for Health and Clinical Excellence.

5. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax. 2000. 55:887–901.

6. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001. 345:1098–1104.

7. Korea Food and Drug Administration. Guideline for treatment of latent tuberculosis infection in patients using TNF antagonist. 2004. Seoul: Korea Food and Drug Administration.

8. Shim TS, Koh WJ, Yim JJ, Lew WJ. Diagnosis and treat of latent tuberculosis infection in Korea. Tuberc Respir Dis. 2004. 57:101–108.

9. Rieder HL. Interventions for tuberculosis control and elimination. 2002. Paris: Internatinal Union Against Tuberculosis and Lung Disease.

10. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982. 60:555–564.

11. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis. 1962. 85:490–510.

12. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999. 3:847–850.

13. Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA. 1986. 255:1579–1583.

14. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis. 1989. 140:1189–1193.

15. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992. 145:36–41.

16. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004. 170:445–449.

17. Haley CA, Stephan S, Vossel LF, Sherfy EA, Laserson KF, Kainer MA. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection. Int J Tuberc Lung Dis. 2008. 12:160–167.

18. Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O'Connell JJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med. 1996. 154:1473–1477.

19. Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med. 1997. 155:1735–1738.

20. Davies P, Ormerod P. The role of four months of rifampicin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2005. 172:509–510.

21. Livengood JR, Sigler TG, Foster LR, Bobst JG, Snider DE Jr. Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure. JAMA. 1985. 253:2847–2849.

22. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999. 353:1843–1847.

23. Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2004. 170:832–835.

24. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006. 166:1863–1870.

25. Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child. 1998. 78:169–171.

26. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med. 1997. 337:801–808.

27. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005. 40:670–676.

28. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007. 45:715–722.

29. Rennie TW, Bothamley GH, Engova D, Bates IP. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J. 2007. 30:728–735.

30. Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med. 2006. 173:922–926.

31. Yun JW, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci. 2007. 22:779–783.

32. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA. 2000. 283:1445–1450.

33. Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med. 2002. 347:1850–1859.

34. Centers for Disease Control and Prevention (CDC). American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep. 2003. 52:735–739.

35. Bergeron KG, Bonebrake RG, Allen C, Gray CJ. Latent tuberculosis in pregnancy: screening and treatment. Curr Womens Health Rep. 2003. 3:303–308.

36. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics. 2002. 109:765–771.

37. Center for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2007. Atlanta: Center for Disease Control and Prevention.

38. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS. 2004. 18:257–264.